The clinical assessment of recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction technologies such as in-vitro fertilization (IVF) has probably been the most extensive clinical trial programme ever performed for the evaluation of a new fertility drug. It started with a pilot study to evaluate the potential of rFSH to stimulate the ovaries in the absence of luteinizing hormone (LH) using various gonadotrophin-releasing hormone (GnRH) agonists. After it became clear that FSH-induced steroidogenesis was not jeopardized even after severe pituitary suppression, comparisons between rFSH and urinary FSH or human menopausal gonadotrophins were made using different GnRH agonists or no agonists at all. In addition, the effects of the route of administration (s.c. or i.m.) were assessed. The study with the strongest statistical power to truly assess clinically relevant differences between rFSH and urinary FSH included ∼1000 patient cycles. It indicated that after
Introduction
Assisted reproduction technologies such as in-vitro fertilization (IVF), gamete intra-Fallopian transfer, zygote intra-Fallopian transfer and intracytoplasmic sperm injection all require ovarian stimulation to increase the number of female gametes, and hence the chances for a successful treatment outcome (Palermo et al., 1992; Healy et al., 1994) . Currently, this is achieved by gonadotrophin treatment with human menopausal gonadotrophins (HMG) or urinary follicle stimulating hormone (FSH) . In addition, the use of gonadotrophin-releasing hormone agonists (GnRHa) is now routine in most IVF clinics, because it enables the adequate timing of oocyte recovery without the potential interference of premature luteinizing hormone (LH) surges (Tarlatzis et al., 1994) . Recent meta-analyses indicate that the use of GnRHa in a long protocol and of FSH-only preparations yields better results in IVF than short protocols and the administration of HMG respectively (Hughes et al., 1992; Daya et al., 1995) .
Disadvantages of urinary gonadotrophins
Until recently, gonadotrophins for medical use were all of a urinary origin. This source implies a number of disadvantages, including low purity (<5%), no absolute source control, a cumbersome collection of urine, some LH contamination even in 'pure' FSH and a low specific activity.
The recently available rFSH is nearly 100% pure without LH contamination, and displays a better batch-to-batch consistency compared with the urinary products because of the carefully controlled manufacturing conditions (Loumaye et al., 1995) .
How to assess comparative safety and efficacy profiles of gonadotrophins
Studies addressing the safety and efficacy of gonadotrophins should be set up prospectively including a randomized design. Ideally, the design should also be double-blind. A sufficient number of patients should be included to provide the trial with an adequate power, generally requiring the cooperation of multiple centres. A recent overview of controlled randomized trials in the infertility field indicated that those using a randomized methodology, including studies comparing the effectiveness of gonadotrophins, were relatively few in comparison with other branches of medicine (Vandekerckhove et al., 1993) . In addition, most studies have suffered from unrealistically small sample sizes, the inappropriate use of crossover design or pseudo-randomization (Vandekerckhove et al., 1993) . Relevant endpoints of comparative trials assessing the properties of gonadotrophins in assisted reproduction are given in Table I . The best endpoint of the efficacy of, for instance, an FSH preparation is the number of large follicles recruited after a fixed period of time using a fixed dose in pituitary-suppressed women. However, in IVF, treatment regimens usually include possibilities of adapting the dose depending on the ovarian response, as assessed by ultrasound and serum oestradiol concentrations. In addition, in multicentre studies with sometimes two or more persons involved in ultrasound scanning, follicle size measurements are not very exact because of interobserver variability (Zador et al., 1988) ; for that reason they are less suitable as an efficacy endpoint. In addition, comparisons between gonadotrophins based on parameters on the day of human chorionic gonadotrophin (HCG) administration will have to take into account the fact that these variables not only reflect the effects of gonadotrophin stimulation itself but also the local ovarian stimulation strategy to reach a predefined criterion, e.g. the number and size of follicles and/or the oestradiol concentration at which HCG is administered. For that reason, efficiency parameters are also important, defined as the total dose (IU) administered and/or the treatment duration.
In multicentre IVF studies comparing gonadotrophins, the most feasible primary efficacy endpoint is therefore the number of oocytes retrieved, because this is the direct result and goal of ovarian stimulation and the parameter that is most easily assessed. Pregnancy rates are less suitable because they rather depend on the number of embryos replaced, which is usually fixed at a certain number. Any surplus of embryos obtained as a result of a higher number of follicles recruited and oocytes retrieved (because of a better performance of the gonadotrophin studied) is therefore not apparent and not reflected in the pregnancy rates directly following the stimulation cycle, unless the gonadotrophin used has a direct effect on the oocyte and subsequently on embryo quality. Therefore it seems that pregnancy rates should include the results of frozenthawed embryo replacements that are the direct (quantitative) result of the preceding gonadotrophin stimulation cycle (Queenan et al., 1995) .
Take-home baby rates, although important in view of the ultimate goal of infertility treatment, should be considered as a less adequate endpoint of gonadotrophin action because other (e.g. obstetric) variables will influence these rates.
Traditionally, safety endpoints of gonadotrophins include the incidence of ovarian hyperstimulation syndrome (OHSS) and multiple gestation, although in IVF the latter is the result of the number of embryos replaced rather than a consequence of the gonadotrophin per se (Hull, 1995) .
To reliably assess the safety and efficacy of rFSH, (Puregon; Organon, Oss, The Netherlands) a large-scale clinical trial programme in IVF has been organized, including studies that were all prospective and randomized; most of them were multicentre investigations. Comparative drugs involved HMG and urinary FSH, and various GnRHa were applied (Table II) .
For technical reasons, these studies were not doubleblind because rFSH was provided in vials and urinary FSH in ampoules. Instead, the studies were conducted assessorblind, implying that the person making the decisions on treatment regimens was not aware of the medication used. The statistical analysis took into account centre effects in multicentre studies by weighting the SE of the treatment difference of the two comparative drugs. The higher the SE (e.g. because of a small number of subjects recruited), the smaller the weight of that centre in the analysis (Whitehead and Whitehead, 1991) . Confidence intervals of 95% of the estimated treatment difference were calculated to assess whether clinically relevant differences were detected.
All analyses were performed on an intent-to-treat basis, including all subjects who received at least one dose of FSH. The main advantages of this rule are that more patients are available for the final analysis of efficacy and that it more closely reflects how physicians evaluate a therapeutic agent in the clinical setting, outside an experimental control.
Data management included monthly on-site monitoring with source verification, and extensive validation and verification procedures (remote data entry, data queries, double data entry, etc.). All trials were conducted according to Good Clinical Practice standards (CPMP Working Party, 1990) .
The FSH content of the ampoules was standardized at 75 IU in-vivo bioactivity per ampoule, using the SteelmanPohley assay (Steelman and Pohley, 1953) as required by the pharmacopoeia (Council of Europe, 1986).
Pilot efficacy study in IVF
In an open pilot efficacy study, the effects of rFSH in assisted reproduction were investigated for the first time using various down-regulation protocols to assess whether the administration of an FSH-only preparation in these circumstances would be sufficient for follicular development and adequate steroidogenesis (Devroey et al., 1994) .
In total, 51 infertile women were treated with rFSH alone (group I), with rFSH in conjunction with buserelin intranasal spray 4 ×150 µg daily in a short (group II) or long protocol (group III), or by using triptorelin in a long protocol, giving a single dose of 3.75 mg i.m. (group IV) or daily s.c. injections of 200 µg (group V). In all women, treatment with rFSH resulted in multiple follicular growth and rises in serum inhibin and oestradiol concentrations. The latter indicated that the amount of remaining LH was sufficient to support FSHinduced oestrogen biosynthesis (see Table III ).
The median number of ampoules and treatment days required in the various treatment groups varied from 21 to 36 ampoules and from 7 to 14 days respectively. The median number of oocytes per group ranged from nine to 11. In all, 43 couples had an embryo transfer and the median number of embryos replaced in each was three per transfer. Eight ongoing pregnancies were achieved, resulting in the birth of nine healthy children (Devroey et al., 1992a (Devroey et al., ,b, 1993 .
rFSH versus urinary FSH Intranasal buserelin in a long protocol
The pivotal trial in the programme encompassed 1000 cycles (Out et al., 1995a) . This study was set up to detect even small differences between both groups. The primary endpoints, as defined prior to starting the study, were the number of oocytes retrieved and the ongoing pregnancy rate, defined as the presence of a vital pregnancy at least 12 weeks after embryo transfer. With a randomization in a 3:2 ratio between rFSH and urinary FSH, 80% power and a two-sided significance level of 5%, a difference of 1.2 oocytes retrieved (assuming SD = 6) and 6% in the pregnancy rates could be detected. The trial was designed as a prospective, randomized, assessor-blind, multicentre study. In all, 18 centres from 11 European countries participated. Selection criteria were age between 18 and 39 years, good physical health, normal weight, at least 1 year of infertility, no male factor, no endocrine abnormalities and normal regular ovulatory cycles. The protocol included: intranasal buserelin downregulation in a long protocol; 150 or 225 IU for the first 4 days, after which the dose was adapted according to ovarian response; HCG administration when at least three follicles ≥17 mm in diameter were seen; and a maximum replacement per transfer of three embryos. Embryo morphology was assessed using a scoring system as published previously (categories I-IV; Staessen et al., 1989) . Embryos with types I and II classification were considered to be of high quality. The results are given in Table IV. The main efficacy parameter, i.e. the number of oocytes retrieved, was consistently higher after rFSH treatment in all 18 participating centres (Figure 1) . The fact that no significant difference was found in the number of follicles ≥17 mm in diameter on the day of HCG administration confirmed that the overall adherence to the protocol was adequate, because at least three follicles of that size had to be present before administering HCG. Follicular growth, as measured by the number of large (≥15 mm in diameter) follicles, started to diverge between rFSH and urinary FSH after ∼5 days of treatment (Figure 2 ). Ongoing pregnancy rates, including frozen-thawed embryo replacements in subsequent natural cycles, were significantly in favour of rFSH (P = 0.05).
Cycle cancellations were seen in 152 subjects who started FSH treatment (rFSH, n = 85, 14.5%; urinary FSH, n = 67, 16.9%; not significantly different). A low ovarian response as the reason for cancellation was reported in 27 subjects in the rFSH group (4.6%) and in 30 subjects in the urinary FSH group (7.6%, P = 0.036, Fisher's exact test, not adjusted for the centre).
The incidence of OHSS leading to hospitalization was seen in 19 out of 585 rFSH-treated subjects (3.2%) versus eight out of 396 urinary FSH-treated subjects (2.0%), which was not significantly different.
In conclusion, this study, which was the largest prospective randomized clinical trial ever performed in IVF, demonstrated a significantly higher number of oocytes, embryos and ongoing pregnancies (efficacy endpoints) using a lower total dose during a shorter treatment period (efficiency endpoints) with a similar incidence of OHSS (safety endpoint) for rFSH when compared with urinary FSH.
Ongoing pregnancy rates with fresh and frozen embryos given in the initial report of the trial (Out et al., 1995) are shown in Table V . Each individual comparison by cycle showed a numerical superiority in pregnancies with rFSH. For purposes of statistical analysis, the proportions in Table  V were represented as a 3 × 2 × 2 contingency table and the resulting frequencies analysed using log-linear modelling (GLM) methods on the algorithm GENSTAT. Individual comparisons failed to reach statistical significance, but the pooled analysis gave a significance probability of <5%, giving evidence of the superiority of rFSH.
S.c. triptorelin in a long protocol
In a multicentre (n = 6) French study comparing rFSH and urinary FSH with the daily s.c. administration of 100 µg triptorelin in a long protocol, 90 subjects were randomized and treated in a 3:2 ratio between rFSH and urinary FSH (Hedon et al., 1995) . The protocol was similar as described above. The results are given in Table VI. Median maximum oestradiol concentrations were 7551 and 5514 pmol/l in the rFSH and urinary FSH groups respectively. None of the between-group differences was statistically significant. There were three cases of OHSS in the rFSH group, of which two had an ongoing pregnancy. No OHSS was seen in the urinary FSH group. 
rFSH versus HMG
In a randomized single-centre study, rFSH and HMG were compared in non-pituitary-suppressed women; 89 women were treated. Subjects received an i.m. gonadotrophin injection of 150-225 IU/day during the first 4 days of treatment, which started on cycle day 3. The further protocol was similar to that discussed previously, except for the criterion to give HCG: to prevent premature luteinization, HCG was already administered when at least two follicles ≥15 mm in diameter were seen. The results are given in Table VII . rFSH compared favourably with HMG with respect to the main efficacy parameters (i.e. the number of oocytes retrieved, 11.2 versus 8.3, and the ongoing pregnancy rates per attempt and per transfer, 22.2 versus 17.1 and 30.8 versus 22.2% respectively). However, none of the differences in this study was significant.
rFSH s.c. versus i.m.
In a randomized study with a similar design to the large IVF study described earlier (Out et al., 1995a) , the efficacy and local side-effects of rFSH administered either s.c. or i.m. were investigated in 118 and 77 subjects respectively who received study medication (Out et al., 1995b) . Local side-effects were assessed daily by the patients, focusing on the presence (mild, moderate, severe) of swelling, itching, redness, pain and bruising at the injection site. The results are given in Table VIII. There were no significant differences in efficacy, efficiency and overall safety endpoints. The only significant difference detected was the occurrence of bruising, which was seen more often (P = 0.019) in the s.c. group. This was attributed to the more superficial injection of the s.c. route, enabling better inspection of the occurrence of bruising compared with the i.m. route. Swelling (%) 5.9 7.8 -9.4 to 5.4
Itching (%) 3.4 6.5 -9.3 to 3.0 a Based on means adjusted for centre. b Defined as the presence of at least one treatment day with symptom(s). c P = 0.019.
Discussion
The large IVF study unambiguously demonstrated that rFSH (Puregon) had a better efficacy profile than urinary FSH: more oocytes were retrieved, more high quality embryos obtained and, ultimately, after replacement of the frozen-thawed embryos, a higher ongoing pregnancy rate was seen (Out et al., 1995a) . A higher activity of rFSH was also suggested by the significantly lower cancellation rate for low response compared with urinary FSH. The two supportive studies demonstrated the same trend towards a higher number of oocytes retrieved and the ongoing pregnancy rate, although these differences were not significantly different probably because of the smaller sample size (Hedon et al., 1995; Jansen and Van Os, 1996) . This emphasizes the need for large studies comprising many patients so as to reliably detect subtle differences between gonadotrophin preparations. Oestradiol concentrations at the day of HCG administration, which can be considered as a sensitive measure of follicle size and number, were higher after rFSH treatment in all studies, again indicating that rFSH has a higher bioactivity than urinary FSH or HMG.
The fact that ongoing pregnancy rates were consistently higher (although not significantly) immediately following embryo transfer in the stimulation cycle suggests that rFSH might have direct beneficial effects on oocyte and embryo quality, leading to higher implantation rates. In addition, the availability of a surplus of embryos improves the possibilities for selection by the embryologist who will replace the best embryos obtained.
Calculation of the cumulative ongoing pregnancy rates including frozen-thawed embryo replacements is the best way to assess the efficacy of an IVF stimulation cycle (Toner et al., 1991; Wang et al., 1994; Queenan et al., 1995) . For rFSH, it was demonstrated that these rates were higher than for urinary FSH. This might be a result of the availability of better quality embryos after rFSH treatment because an equal number of embryos in these natural cycles was replaced in both groups, or the more obvious reason that merely the availability of more embryos will ultimately lead to more pregnancies. Because the reported pregnancy rates do not include the replacements of all embryos available, differences in the projected ongoing pregnancy rate after using all available embryos will be even more than the 6% difference reported in favour of rFSH.
The reasons for the higher effectiveness of rFSH are not known. Possible explanations include the content of the more basic isohormones in rFSH, differences in pharmaceutical formulation, the presence of FSH-inhibiting substances in urinary FSH and small differences at the carbohydrate level.
Future research is needed to elucidate the influence of these factors on the better performance of rFSH. In fact, its higher activity is surprising in view of the equal contents of ampoules of both rFSH and urinary FSH, namely 75 IU in-vivo bioactivity, as determined by the in-vivo Steelman-Pohley rat assay (Steelman and Pohley, 1953) . If this in-vivo bioassay used to standardize the bioactivity per ampoule was predictive for efficacy in IVF, by definition no difference could have been detected in clinical trials. Apparently, this bioassay, which is required as per pharmacopoeia (Council of Europe, 1986) , is not valid for a proper clinically relevant assessment of the bioactivity of an FSH preparation. This is not surprising because in-vivo bioactivity is measured as the weight augmentation of ovaries from rats treated with FSH and a surplus of HCG in a comparative way with an international reference preparation. Microscopical examination of these ovaries reveals many luteinized unruptured follicles that contain large volumes of follicular fluid which contribute disproportionately to the weight augmentation (unpublished observations).
It is unlikely that the known relatively large inter-and intra-assay variations of the Steelman-Pohley assay, leading to coincidental differences in the number of international units per ampoule, account for the differences found. Apart from the fact that pharmaceutical companies can easily overcome this problem by multiple analyses and careful standardizing of their procedures, a direct linear relationship between the mean daily dose or the total dose given to reach the criterion to administer HCG and the number of oocytes retrieved could not be confirmed (Out et al., 1995a) .
Clinical trials have also been conducted comparing urinary FSH with another rFSH preparation (Gonal-F; AresSerono, Geneva, Switzerland). One completed study has been published assessing the effectiveness of this rFSH in IVF (Recombinant Human FSH Study Group, 1995) . Table IX summarizes the main results of that study.
Unfortunately, confidence intervals were not given, but the small sample size obviously implies that clinically relevant differences could not be detected in this study. Despite this, these data strongly suggest that differences between the rFSH preparations Puregon and Gonal-F exist, given the significantly lower oestradiol concentrations and number of follicles ≥14 mm in diameter on the day of HCG administration compared with urinary FSH, which is completely in contrast to the results obtained in the comparison of Puregon and urinary FSH. This may be expected because of the complexity of the recombinant DNA preparations involved. The different natures of the two rFSH preparations are confirmed by the fact that the regulatory authorities have issued two distinct International Non-proprietary Names (INN), i.e. follitrophin alpha (Gonal-F) and follitrophin beta (Puregon), to emphasize the fact that both compounds should be considered as distinct new active substances. Direct comparisons between both preparations will ultimately demonstrate whether these compounds have a different clinical efficacy.
Efficiency endpoints, defined as the treatment duration and the total dose administered, were significantly advantageous for rFSH. This indicates a double benefit: not only is the number of oocytes retrieved higher, but pre-ovulatory conditions are reached using fewer ampoules in a shorter treatment period. Obviously, this means improved convenience for the patients and the fertility specialists.
No significant differences between rFSH and urinary FSH or HMG were found with respect to the incidence of the most important side-effect, OHSS. In the large IVF study (Out et al., 1995a) , severe OHSS (hospitalization) was seen in 3.2% of women after rFSH treatment versus 2.0% in the urinary FSH group. However, because risk factors for the development of OHSS, such as a high number of follicles and high oestradiol concentrations, were seen more often in the rFSH group, adequate monitoring of the ovarian response remains essential to prevent this complication.
No antibodies against FSH or Chinese hamster ovary cell-derived proteins were detected. In addition, no clinically relevant changes in the biochemical or haematological parameters were found, nor significant trends in vital signs, as assessed before and after treatment. The s.c. route enabling self-administration was well tolerated, as assessed prospectively in comparison with the i.m. route. 
Conclusion
An rFSH preparation (Puregon) has indisputably demonstrated a better clinical performance than urinary FSH in assisted reproduction, as assessed in the largest prospective randomized IVF trial ever performed. This was ultimately shown by an increased ongoing pregnancy rate when frozen-thawed embryo replacements were included. No significant differences in the safety profiles were seen, which altogether makes rFSH the first choice of treatment in infertile couples who need gonadotrophin ovarian stimulation.
